[Experimental] List of manuscripts available for review volunteers
2 manuscripts available for review volunteers
November 30, 2017
The science of vaccinology has substantially progressed over the past 40 years and has remarkably helped to prevent or contain diseases. Oncovaccines development, however, has been less steady due to some unique challenges presented by cancer. With the recent advancement of our insight in oncoimmunology, vaccine technology, and medicine, we hope to better comprehend the intricate process of antitumor immunity to combat our old adversary. Numerous prophylactic and one therapeutic oncovaccine have been authorized by Food and Drug Administration (FDA) for manufacturing and marketing. Where prophylactic vaccines have seen momentous success in terms of effectiveness and clinical acknowledgment, a significant amount of research is still lacking to achieve same destiny for therapeutic vaccines. This review shines a light on the development of both types of vaccines and their acceptance into the marketplace. We would likewise discuss FDA approved products, their mechanism of antitumor immunity, indications, and uses.
November 20, 2017

Background. Different anticancer drugs are used in combination or alone to treat breast cancer depending upon the status of the patient. Oncologists need to know a drug’s efficacy; therefore, they compare different chemotherapies by considering side effects and overall survival so that suitable drugs can be prescribed. We present a comparison of adjuvant chemotherapies treating breast cancer with docetaxel plus cyclophosphamide (TC) and doxorubicin plus cyclophosphamide (AC) showing pathological markers and overall survival.

Method. For 4 to 8 cycles, (after every 21 days) out of 358 patients, 189 received TC (140 ml/m2 of docetaxel (IV) plus 1000 mg/m2 of cyclophosphamide) and 169 women were treated with AC (50/100 ml/m2 of doxorubicin (IV) plus 1000 mg/m2 of cyclophosphamide. On the basis of patients’ assessment by pathological markers, side effects of docetaxel, doxorubicin and cyclophosphamide are listed in our database using R programming language. The common factors and side effects given in MedlinePlus, NIH US database and from our database are separated to be included in comparison for this study. Statistically, we used Chi-Square Test for Homogeneity of Proportions at α = 0.05.

Results. There was no significant difference between proportions of patients with vomiting, extreme tiredness, diarrhoea, mild anaemia, stability and overall survival because p value > 0.05. However, p value < 0.05 for AC remains less toxic by 22.6%, 25.7% and 25.3% than TC in changes in taste, muscle pain and hands burning respectively, whereas TC remains less toxic by 52.9%, 26.3%, 11.3%, 32.5%, 15.5% and 1.75% in dizziness, sore throat, moderate anaemia, weight loss, blood transfusion and haemoglobin level respectively.

Discussion. TC is less toxic than AC in more aspects, whereas both combinations have same overall survival rate.


Is this open peer review?

No, peer review is still single-blind and all recommendations are private between the authors and Academic Editor. However, any reviewer has the option to sign their report, and once accepted for publication then that review can be shown publicly - again this is optional.

Will I be guaranteed to review if I volunteer?

No. Volunteering is not a guarantee that you will be asked to review. This is for many reasons. For one, reviewers must have relevant qualifications for any manuscript and void of any conflicts of interest. Additionally, it could be that enough reviewers have accepted an invitation to review already, in which case we would not invite any more.

Why aren't there more manuscripts available?

Manuscripts are shown when authors have opted-in for obtaining reviewers through the reviewer-match service. Additionally, there may already be enough reviewers found through other means, for example, invitations sent by the Academic Editor in charge.

What are the editorial criteria?

Please visit the editorial criteria page for initial guidance. You will also be given additional information if invited to review.